{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-002831","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.731016+00:00","generated_at":"2026-05-28T04:03:03.364443+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kyverna outlines 2025 priorities; pivotal SPS trial 40% enrolled, BLA filing targeted for 2026","bullets":["40% enrolled in pivotal Phase 2 KYV-101 trial for stiff person syndrome; BLA filing targeted for 2026.","Cash runway into 2027 with $321.6M cash and securities as of Sep 30, 2024.","Myasthenia gravis: confirm registrational path 1H 2025, interim Phase 2 data 2H 2025.","Lupus nephritis: Phase 1 data expected 2H 2025; KYV-102 IND filing 2H 2025.","Company pivoting to late-stage development and commercialization with CD19 CAR T construct KYV-101."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-002831","json":"https://secwatch.observer/filing/0001213900-25-002831.json","markdown":"https://secwatch.observer/filing/0001213900-25-002831.md","text":"https://secwatch.observer/filing/0001213900-25-002831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000121390025002831/0001213900-25-002831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000121390025002831/ea0227480-8k_kyverna.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:03:03.364443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}